Scinai Immunotherapeutics (NASDAQ:SCNI) & Mesoblast (NASDAQ:MESO) Head to Head Review

Mesoblast (NASDAQ:MESO) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Valuation and Earnings

This table compares Mesoblast and Scinai Immunotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$5.90 million	132.52	-$87.96 million	($1.12)	-6.12
Scinai Immunotherapeutics	$284,000.00	5.82	-$6.50 million	($261.70)	-0.01

Scinai Immunotherapeutics has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Mesoblast has a beta of 3.47, suggesting that its stock price is 247% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.48, suggesting that its stock price is 148% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Mesoblast and Scinai Immunotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	3	0	3.00
Scinai Immunotherapeutics	0	0	0	0	N/A

Mesoblast presently has a consensus price target of $11.00, suggesting a potential upside of 60.58%. Given Mesoblast’s higher possible upside, equities research analysts plainly believe Mesoblast is more favorable than Scinai Immunotherapeutics.

Profitability

This table compares Mesoblast and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Scinai Immunotherapeutics	N/A	N/A	-107.47%

Summary

Mesoblast beats Scinai Immunotherapeutics on 7 of the 11 factors compared between the two stocks.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.